In his monthly column for Omnicell’s blog, 340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022. They focus on:
- the U.S. Supreme Court case on Medicare reimbursement to 340B hospitals
- where the contract pharmacy standoff is ultimately headed
- next steps in the effort by 340B providers to challenge what they perceive as discriminatory reimbursement by third party payors as well as the congressional effort to establish a neutral clearinghouse to resolve the duplicate discount challenge.
You can read the piece here.
In his monthly column for Omnicell’s blog, 340B Report Publisher and Chief Executive Officer Ted Slafsky makes three big predictions for the 340B program for 2022.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
